These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17443478)

  • 1. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.
    Behler CM; Vittinghoff E; Lin F; Chung RT; Peters MG; Robbins GK; Volberding PA
    Clin Infect Dis; 2007 May; 44(10):1375-83. PubMed ID: 17443478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
    Talal AH; Liu RC; Zeremski M; Dimova R; Dove L; Pearce D; Hassanein T; Doonquah L; Aboulafia D; Rodriguez J; Bonilla H; Galpin J; Aberg JA; Johnston B; Glesby MJ; Jacobson IM
    J Acquir Immune Defic Syndr; 2011 Nov; 58(3):261-8. PubMed ID: 21876446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
    Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
    Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
    J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
    Voigt E; Schulz C; Klausen G; Goelz J; Mauss S; Schmutz G; Jessen H; Weitner L; Mutz A; Schranz D; Rockstroh JK;
    J Infect; 2006 Jul; 53(1):36-42. PubMed ID: 16269184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
    Glesby MJ; Bassett R; Alston-Smith B; Fichtenbaum C; Jacobson EL; Brass C; Owens S; Sulkowski M; Race EM; Sherman KE;
    J Infect Dis; 2005 Mar; 191(5):686-93. PubMed ID: 15688281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
    Arizcorreta A; Brun F; Fernández-Gutiérrez C; García Juárez R; Guerrero F; Pérez-Guzmán E; Girón-González JA
    Clin Microbiol Infect; 2004 Dec; 10(12):1067-74. PubMed ID: 15606633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
    Crespo M; Sauleda S; Esteban JI; Juarez A; Ribera E; Andreu AL; Falco V; Quer J; Ocaña I; Ruiz I; Buti M; Pahissa A; Esteban R; Guardia J
    J Viral Hepat; 2007 Apr; 14(4):228-38. PubMed ID: 17381714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
    Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
    Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
    Bräu N
    J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
    Collantes RS; Younossi ZM
    J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S9-13. PubMed ID: 15597026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.